OR6C4

Across TCGA pan-cancer cohorts, OR6C4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR6C4 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher OR6C4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR6C4 expression acts as an unfavorable survival marker.

STAD, UCEC, and COAD are the cancer types where OR6C4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.169	0.730	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	DFS	Median	All	0.220	0.793	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

OR6C4–STAD (OS)

Open the STAD breakdown →